

Abbreviated Drug Class Review: Proton Pump Inhibitors

Updated August 2006

VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel

The following recommendations are based on current medical evidence and expert opinion from clinicians. The content of the document is dynamic and will be revised as new clinical data becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. The clinician should utilize this guidance and interpret it in the clinical context of the individual patient situation.

Objectives

1. To provide an abbreviated review of the five proton pump inhibitors (PPIs) currently available by prescription in the U.S. for the treatment of acid-related gastrointestinal disorders (Table 1).^a
2. To provide a brief comparison of the proprietary and nonproprietary (generic) preparations of omeprazole and of the five PPIs to aid in negotiating contracts for these agents for the Veterans Health Administration.

Table 1 Proton pump inhibitors

PPI	Esomeprazole	Lansoprazole	Omeprazole	Pantoprazole	Rabeprazole
<i>Proprietary products</i>					
Brand Name	Nexium	Prevacid Prevacid SoluTabs	Prilosec Zegerid [†]	Protonix	Aciphex
Manufacturer	AstraZeneca	TAP Pharm	Astra Santarus	Wyeth-Ayerst	Eisai/Janssen
<i>Nonproprietary products</i>					
Manufacturer	—	—	Kremers Urban / Schwarz, others	—	—

[†] Omeprazole / Sodium bicarbonate (immediate-release)

Formulations

The main difference between proprietary and generic omeprazole formulations result from the manufacturing process. Each capsule of Prilosec[®] contains enteric-coated granules, the cores of which consist of omeprazole and an alkaline-reacting compound. Each capsule of generic omeprazole contains identical, enteric-coated microtablets, the cores of which contain omeprazole without an alkaline-reacting compound.

The two products also differ in capsule strengths and appearance. Prilosec is available in 10-, 20-, and 40-mg amethyst or apricot / amethyst capsules. Generic omeprazole comes in only two strengths (10 and 20 mg) and the capsules are white or gold / white. The 10-mg capsule of generic omeprazole contains 10 microtablets and the 20-mg capsule contains 18 microtablets.

Proprietary omeprazole has been used off-label as an extemporaneously formulated bicarbonate-based suspension (Simplified Omeprazole Suspension).¹⁻⁵ Studies performed by the manufacturer have shown that generic omeprazole, when used to make a Simplified Omeprazole Suspension, is stable without color change under refrigeration (4 °C) for 30 days, and is also stable at room temperature (25 °C) for 30 days, although the suspension turned a light brown color during the 30-day storage period (C. Bretzmann, written communication, 29 June 2006).

Esomeprazole and lansoprazole are also formulated as capsules containing enteric-coated pellets and granules, respectively. Pantoprazole and rabeprazole are available in tablets. Lansoprazole has two additional FDA-approved oral dosage forms, the orally disintegrating tablets and granules for liquid suspension for individuals with difficulty swallowing capsules (not for enteral tube administration). Like proprietary omeprazole, lansoprazole has been prepared off label as a bicarbonate-based suspension (Simplified Lansoprazole Suspension, SLS).^{3,6-8} Only pantoprazole is available in an intravenous formulation.

The oral PPIs also differ in excipients. Both proprietary and generic omeprazole contain lactose, while the other PPIs do not.

^a This review does not include nonprescription omeprazole magnesium (Prilosec 1, Procter and Gamble), now available in salmon-colored, 20.6-mg tablets (equivalent to 20 mg omeprazole).

Table 2 Proprietary Proton Pump Inhibitor Formulations

PPI	Esomeprazole	Lansoprazole	Omeprazole	Omeprazole / Sodium Bicarbonate	Pantoprazole	Rabeprazole
Main Oral Dosage Form	DR Caps	DR Caps	DR Caps	IR Caps	DR EC Tabs	DR EC Tabs
Contents of Capsules	EC Pellets	EC Granules	EC Granules	Powder (containing 1100 mg sodium bicarbonate)	—	—
Strength (Color)	20, 40 mg (Amethyst)	15 mg (Pink / Green) 30 mg (Pink / Black)	10 mg (Apricot / Amethyst) 20 mg (Amethyst) 40 mg (Apricot / Amethyst)	20 (Lt blue / white) 40 (Dk blue / white)	20, 40 mg (Yellow)	20 mg (Lt yellow)
Excipients	Talc	Sucrose	Lactose, Mannitol	Croscarmellose sodium, magnesium stearate	Mannitol	Mannitol
Other Dosage Forms	Powder for injection 20, 40 mg	<i>DR Orally Disintegrating Tabs</i> 15, 30 mg (White / Orange) <i>DR Susp</i> (30 ml): 15, 30 mg <i>Simplified Lansoprazole Suspension</i> [†] 30 mg/10 ml (OLU) Powder for injection 30 mg	<i>Simplified Omeprazole Suspension</i> [†] 20 mg/10 ml (OLU)	<i>IR Powder for Oral Susp (non-EC, IR)</i> 20, 40 mg (each with 1680 mg of sodium bicarbonate) [‡]	<i>I.v. injection:</i> 40 mg / vial	—

Caps = Capsules; DR = Delayed-release; EC = Enteric-coated; IR = Immediate-release; I.v. = Intravenous; OLU = Off-label Use; Susp = Suspension; Tabs = Tablets

[†] Bicarbonate-based simplified suspensions of lansoprazole and omeprazole are extemporaneously compounded. Simplified Lansoprazole Suspension: 3 mg/ml 8.4% sodium bicarbonate; stable for 14 days at room temperature or 28 days refrigerated (non-oral syringe).⁷ Simplified Omeprazole Suspension: *Proprietary Omeprazole*—2 mg/ml 8.4% sodium bicarbonate; stable for 1 week at room temperature or 24 weeks frozen (non-oral syringe); protect from light

[‡] Since both the 20 mg and 40 mg capsules contain the same amount of sodium bicarbonate (1100 mg or 13 mEq; equivalent to 300 mg Na+), two capsules of 20 mg are not equivalent to one 40-mg capsule. Likewise, since both powder for suspension contain the same amount of sodium bicarbonate (1680 mg or 20 mEq; equivalent to 460 mg Na+), two packets of 20 mg are not equivalent to one 40-mg packet.

Table 3 Nonproprietary proton pump inhibitor formulation

PPI	Omeprazole
Brand Name	—
Manufacturer	Kremers Urban / Schwarz, various others
Main Oral Dosage Form	DR Caps
Contents of Capsules	EC Microtablets
Strength (Color)	10 mg (White) 20 mg (Gold / White)
Excipients	Lactose
Other Dosage Forms	Simplified Omeprazole Suspension [†]

Caps = Capsules; DR = Delayed-release

[†] ; Simplified Nonproprietary Omeprazole Suspension: add 20 mg omeprazole + 5 ml of 8.4% sodium bicarbonate injection solution in plastic, amber-colored, 10-ml oral syringe (omeprazole concentration, 4 mg/ml)¹; vortex for about 3 minutes and shake until all microtablets disintegrated; stable under refrigeration (4 °C) or room temperature (25 °C) for 30 days, although the suspension turns a light brown color at room temperature.

Indications and Dosage

The PPIs are FDA-approved for a variety of gastrointestinal acid-related disorders (see Table 4). The approved therapeutic indications, dosage and administration recommendations, as well as the clinical studies described in the package inserts for nonproprietary omeprazole and proprietary omeprazole (Prilosec) are identical.^{9,10}

Lansoprazole and omeprazole have the greatest number of approved indications for management of duodenal ulcers, gastric ulcers, GERD, or pathologic hypersecretory conditions.

Table 4 FDA-approved indications, off-label uses (OLUs), and dosages for PPIs

Indication	Esomeprazole	Lansoprazole	Omeprazole	Pantoprazole	Rabeprazole
Duodenal ulcers					
Healing	—	15 mg q.d. × 4 wk	20 mg q.d. × 4 to 8 wk	40 mg q.d. × 2 to 4 wk (OLU)	20 mg q.d. × ≥ 4 wk
Maintain healing	—	15 mg q.d.	10 to 20 mg q.d. (OLU)	—	—
Eradicate <i>Helicobacter pylori</i> associated with duodenal ulcers	40 mg q.d. × 10 d in 3-drug regimen [†]	30 mg b.i.d. × 10 or 14 d in 3- drug regimen [†] 30 mg q8h × 14 d in 2-drug regimen [†]	20 mg b.i.d. × 10 d in 3-drug regimen [†] 40 mg q.d. × 14 d in 2-drug regimen [†]	—	20 mg b.i.d. × 7 d in 3-drug regimen [†]
Prevention of re-bleeding of high-risk duodenal ulcers	—	—	20 mg q6h or 40 mg q12h x 5 d (OLU)	—	—
Gastric ulcers					
Healing, non-NSAID-related	—	30 mg q.d. × ≤ 8 wk	40 mg q.d. × 4 to 8 wk	40 mg q.d. × 4 or 8 wk (OLU)	20 mg q.d. × 3 or 6 wk (OLU)
Healing, NSAID-related	—	30 mg q.d. × 8 wk	—	40 mg q.d. × 12 wk (OLU)	—
Reduce risk, NSAID-related	20 or 40 mg q.d. x ≤ 6 mo	15 mg q.d. × ≤ 12 wk	—	40 mg q.d. × 12 wk (OLU)	—
Prevention of re-bleeding after acute bleeding of high-risk, gastric ulcers	—	—	20 mg q6h or 40 mg q12h x 5 d (OLU)	—	—
GERD					
Relieve symptoms	20 mg q.d. × 4 to 8 wk	(inc. NERD) 15 mg q.d. × ≤ 8 wk	(NERD) 20 mg q.d. × 4 wk	40 mg q.d. × 4 or 8 wk (OLU)	20 mg q.d. × 4 to 8 wk
Maintain symptom control in nonerosive reflux disease, on- demand therapy	20 mg q.d. p.r.n. (OLU)	—	20 mg q.d. p.r.n. (OLU)	—	—
Healing of erosive or ulcerative esophagitis	20 or 40 mg q.d. × 4 to 16 wk	30 mg q.d. × 8 to 16 wk	20 mg q.d. × 4 to 8 wk	40 mg q.d. × 8 to 16 wk	20 mg q.d. × 4 to 16 wk
Maintain healing of erosive or ulcerative esophagitis	20 mg q.d.	15 mg q.d.	20 mg q.d.	40 mg q.d.	20 mg q.d.
Maintain healing of erosive or ulcerative esophagitis, alternate- day dosing	—	30 mg q.o.d. (OLU)	20 to 40 mg q.o.d. (OLU-N)	—	—
Short-term treatment of GERD with history of erosive esophagitis, as an alternative to oral therapy	—	—	—	40 mg q.d. × 7 to 10 d (i.v.)	—
Posterior laryngitis, GERD-related	—	—	20 or 40 mg q.h.s. × 6 to 24 wk or 20 to 40 mg b.i.d. × 4 to 12 wk (OLU)	—	—
Diagnosis of GERD-related noncardiac chest pain	—	30 mg q.d. × 4 wk (OLU)	20 mg b.i.d. × 14 d (OLU)	—	—
Other					
Reduction of risk of upper gastrointestinal bleeding in critically ill patients	—	—	40 mg initially and after 6 to 8 h, then 40 mg q.d. x up to 14 d (IR OME/SB powder for oral susp)	—	—
Hypersecretory conditions	—	60 to 180 mg/d in 1 or 2 divided doses	60 to 360 mg/d in 1 to 3 divided doses	80 mg/d (p.o.) or 160 mg/d (i.v.) in 2 divided doses, up to 240 mg/d	60 to 120 mg/d in 1 or 2 divided doses

Sources: ⁹⁻⁵³

All doses refer to oral administration except as indicated.

Updated versions can be found at: www.pbm.va.gov or vawww.pbm.va.gov.

Final 06/21/01 (Revised 08/06)

OLU = Off-label use supported by at least one published double-blind, randomized controlled trial comparing PPI to placebo or active comparator or rated as having at least "fair" documentation in *Off-Label Drug Facts* (2003).²⁵ Abstracts are excluded.

OLU-N = Off-label use supported by at least one noncomparative, double-blind, randomized trial or at least one comparative open-label randomized trial. Abstracts are excluded.

IR OME/SB = Immediate-release omeprazole / sodium bicarbonate

NERD = Non-erosive (endoscopy-negative) reflux disease

† Esomeprazole, omeprazole, lansoprazole, and rabeprazole are approved for *H. pylori* eradication in three-drug combinations with amoxicillin (1 gm) and clarithromycin (500 mg) given twice daily. Lansoprazole (with amoxicillin 1 gm) and omeprazole (with clarithromycin 500 mg) are also approved for the same indication in two-drug combinations.

Immediate-release omeprazole / sodium bicarbonate is the only immediate-release PPI and the only PPI approved for reduction of risk of upper gastrointestinal bleeding in critically ill patients. Lansoprazole is the only PPI approved for healing or risk reduction of nonsteroidal anti-inflammatory drug (NSAID)-related gastric ulcers, and there is off-label experience with pantoprazole for this indication.¹¹ Off-label use of pantoprazole in the management of duodenal and gastric ulcers has been documented in a number of double-blind randomized controlled trials (DBRCTs).¹²⁻¹⁹

All of the PPIs have approved indications for treatment of erosive or ulcerative reflux esophagitis. Healing and maintenance of erosive esophagitis are currently the main approved indications for pantoprazole, which is the first PPI available in a parenteral (intravenous) formulation for the short-term (7- to 10-day) treatment of GERD in patients who are unable to continue taking the oral tablets. Omeprazole has dosing recommendations specifically for treatment of non-erosive reflux disease.

All of the PPIs except esomeprazole have approved indications for the treatment of pathologic hypersecretory conditions such as Zollinger-Ellison syndrome.

There is sufficient evidence to support unique off-label uses for omeprazole, lansoprazole, and esomeprazole. Orally administered omeprazole has been used for prevention of re-bleeding of peptic ulcers with high-risk endoscopic stigmata following endoscopic therapy^{49,50} and for treatment of reflux laryngitis.^{25,46} Alternate-day dosing of either lansoprazole or omeprazole has been reported to be effective in preventing recurrence of erosive esophagitis.²⁵ Esomeprazole⁵² and omeprazole⁵³ given on-demand for up to 6 months have been shown to be efficacious in controlling heartburn in patients with nonerosive (endoscopy-negative) reflux disease, with esomeprazole 40 mg no better than 20 mg daily as needed⁵⁴ and omeprazole 20 mg superior to 10 mg daily as needed.⁵³ Standard-dose lansoprazole (30 mg per day)⁴⁸ and double-dose omeprazole (40 mg per day)⁴⁷ have also been useful in the diagnosis of noncardiac chest pain associated with GERD.

Dosing in special patient populations

Dosage adjustment of the PPIs may be necessary in patients with hepatic impairment (Table 5). None of the PPIs require dosage adjustment in renal impaired or elderly patients. Race-related pharmacokinetic differences have been noted in Asian patients treated with lansoprazole, omeprazole, and rabeprazole.

Table 5 Dosage adjustments in special populations

Population characteristic	Esomeprazole magnesium	Lansoprazole	Omeprazole	Pantoprazole	Rabeprazole
Hepatic impairment	Severe impairment (Child Pugh Class C): Max. ≤ 20 mg q.d.	Severe impairment: decrease dose	Consider decrease in dose	No adjustment (highest dose used, 40 mg q.d.)	Severe impairment: use caution
Renal impairment	No adjustment	No adjustment	No adjustment	No adjustment	No adjustment
Elderly	No adjustment	No adjustment	No adjustment	No adjustment	No adjustment
Gender	No adjustment	No adjustment	No data	No adjustment	No adjustment
Race	No data	Limited data suggests increased AUC in Asians; no dosing recommendations	Consider decreasing dose in Asians	No data	AUC increased 50% to 60% in Japanese using different formulations; no dosing recommendations

Sources: ^{9,10,21-24}

Compliance factors

Alternative dosing packages or methods of administration that may improve patient convenience or aid patient adherence to medication regimens are available for all of the PPIs except rabeprazole (Table 6). According to the manufacturer (Janssen Pharmaceutica, Inc., product information, verbal communication, October 2003), there are currently no alternative methods of administration for rabeprazole (which is available only as delayed-release tablets that must be swallowed whole) in patients who have difficulty swallowing or are unable to take oral medication.

Generic omeprazole capsules may be opened and the microtablets sprinkled on applesauce. Unlike proprietary omeprazole, the stability and pH effects of generic omeprazole mixed in orange juice have not been studied.

Table 6 Alternative methods of administration

Indication / Problem	Esomeprazole	Lansoprazole	Omeprazole	Pantoprazole
<i>H. pylori</i> eradication	—	Prevpa® (lansoprazole / amoxicillin / clarithromycin) dosing package	—	—
Difficulty swallowing capsules	Open capsule and sprinkle pellets in applesauce, tap water, orange juice, apple juice, or yogurt.	Delayed-release capsules. Open capsule and sprinkle granules in applesauce, <i>Ensure</i> pudding, cottage cheese, yogurt, or strained pears. Alternatively, mix granules in 60 ml of apple, orange, or tomato juice and swallow immediately. Orally disintegrating tablets. Place tablet on tongue, allow to disintegrate (about 1 minute), then swallow. Delayed-release oral suspension. Note: not recommended for administration via enteral tubes.	Open capsule and sprinkle granules (proprietary product) or microtablets (nonproprietary product) in applesauce. Orange juice has also been used with proprietary omeprazole (OLU). ⁵⁵ Omeprazole/Sodium bicarbonate IR CAPSULES should NOT be opened and sprinkled on food. They should be swallowed intact with water only.	—
Enteral tube administration	Open DR capsules and empty intact granules into a 60 mL syringe and mix with 50 mL of water. Replace the plunger and shake the syringe vigorously for 15 seconds. Hold the syringe with the tip up and check for granules remaining in the tip. Attach the syringe to a NG tube and deliver the contents of the syringe through the NG tube into the stomach. After administering the granules, the NG tube should be flushed with additional water. Do not administer the pellets if they have dissolved or disintegrated.	DR Capsules: Open capsules, mix intact granules with about 40 ml of apple juice (not other liquids), then inject into NG tube. Oral disintegrating tablets DR: For administration via an NG tube, place a 15-mg tablet in a syringe and draw up 4 mL water, or place a 30-mg tablet in a syringe and draw up 10 mL water. Shake gently to allow for a quick dispersal. After the tablet has dispersed, inject through the NG tube into the stomach within 15 minutes. Refill the syringe with approximately 5 mL of water, shake gently, and flush the NG tube. Extemporaneously compounded Simplified Lansoprazole Suspension (OLU). [†] NOTE: Granules for Oral Suspension DR are NOT recommended for enteral tube administration.	Open capsules of proprietary omeprazole, mix intact granules with orange juice, then inject into enteral tube (OLU). ³ IR Omeprazole-sodium bicarbonate oral powder for suspension: Suspend enteral feeding at least 3 h before and for 1 h after administration of omeprazole powder for suspension. Mix with 20 ml of water. Other liquids or food should not be used. After administration, wash suspension through tube with 20 ml water. Extemporaneously compounded Simplified Omeprazole Suspension (OLU). [†]	—
Unable to continue oral medication	—	—	—	Intravenous formulation

NG = Nasogastric; OLU = Off-label use

[†] Bicarbonate-based simplified suspensions of lansoprazole and omeprazole are extemporaneously compounded. Simplified Lansoprazole Suspension: 3 mg/ml 8.4% sodium bicarbonate; stable for 14 days at room temperature or 28 days refrigerated (non-oral syringe).⁷ Simplified Proprietary Omeprazole Suspension: 2 mg/ml 8.4% sodium bicarbonate; stable for 1 week at room temperature or 24 weeks frozen (non-oral syringe); protect from light.¹ Simplified Nonproprietary Omeprazole Suspension: See footnote to Table 3.

Safety

Common adverse events

All of the available PPIs have been well tolerated in short- and long-term clinical trials.^{9,10,21-24,45} The estimated number of patients exposed to the PPIs during the premarketing clinical trials are 10,000 for esomeprazole, more than 10,000 for lansoprazole, 3096 for omeprazole, more than 11,000 for pantoprazole, and 2900 for rabeprazole. The adverse event information for generic omeprazole is identical to that for proprietary omeprazole.

The most frequently reported adverse events (those occurring in greater than or equal to 2% of patients in at least one treatment group for any PPI) in placebo-controlled trials generally affected the gastrointestinal or central nervous system

(Table 7). Headache, diarrhea, and abdominal pain were usually the most common adverse events. The frequency of headache with lansoprazole occurred in more than 1% of patients (N > 10,000) but was more common on placebo. Dose-related increases in the frequency of diarrhea were noted in premarketing clinical trials for lansoprazole. For the other PPIs, dose-related adverse events were either not observed (pantoprazole, rabeprazole) or not reported (esomeprazole, omeprazole). Overall, the adverse event profiles of the PPIs in placebo-controlled trials were similar.

Pooled results of premarketing head-to-head trials^{21,24} and other direct comparisons of PPIs (omeprazole versus other PPIs, and lansoprazole versus esomeprazole or pantoprazole) in DBRCTs have consistently found the safety and tolerability of PPIs to be similar.^{12,17,18,24,29,31-33,56-81} One exception was a crossover DBRCT that found rabeprazole to be superior to omeprazole for “absence of unwanted side effects” and “presence of positive side effects” (p = 0.0467 and p = 0.0188, respectively).⁸² There was, however, no significant treatment difference in total treatment preference score (the primary efficacy variable) and no difference in tolerability.

Table 7 Most frequently occurring adverse events in placebo-controlled trials (≥ 2% of patients in at least one treatment group for any PPI)

Adverse Event	Frequency as percentage (%) of patients				
	Esomeprazole	Lansoprazole	Omeprazole	Pantoprazole	Rabeprazole
N (Exposed)	NR	2768	465	521	1552
<i>Central Nervous System</i>					
Headache	[3.8]	> 1%	2.9 [2.4]* to 6.9*	[6]	[2.4]*
<i>Gastrointestinal System</i>					
Abdominal pain	[3.8]	[2.1]*	2.4 [0.4] to 5.2	[1]	NR
Diarrhea	[4.3]	[3.8]*	3.0 [1.9] to 3.7*	[4]*	NR
Flatulence	—	< 1	2.7	[2]	NR
Nausea	—	[1.3]*	2.2 [0.9] to 4.0	[2]	NR
Vomiting	—	< 1	1.5 [0.4]	[2]	NR

Sources: Package inserts^{9,10,21-24}

Rates are not directly comparative between PPIs because the frequencies reflect the results of different clinical trials, the method of collecting adverse event data in the trials may have differed, and the presentation of adverse events in package inserts varied.

NR = Not reported. NR for adverse event rate means that the adverse event was listed and was not rare (not ≤ 1/1000), but the frequency was not specified. Dash marks indicate adverse event was not mentioned in the package insert under placebo-controlled trials; however, the adverse event may have been reported in other comparative clinical trials.

* Frequency of adverse event was greater on PPI than on placebo (no statistical analyses).

Immediate-release omeprazole / sodium bicarbonate differs from the delayed-release PPIs in that it is contraindicated in patients with metabolic alkalosis and hypocalcemia and should be used with caution in patients with acid-base disorders. Its sodium content must be considered in patients on sodium-restricted diets. It also has the potential for medication errors if two 20-mg capsules, which together contain 2200 mg of sodium bicarbonate (600 mg Na⁺), are substituted for one 40-mg capsule, which contains 1100 mg of sodium bicarbonate, the same amount in one 20-mg capsule.

Studies in rats have found PPI-induced hyperplasia of gastric enterochromaffin-like (ECL) cells and, in some cases, gastric neuroendocrine cell tumors, which may result from chronic hypergastrinemia.^{9,10,21-24,45} Time- and dose-related increases in the frequency of ECL cell hyperplasia and hypergastrinemia have been observed in patients treated with PPIs for 6 months to 5 years in clinical trials.^{9,10,21-24,45,83} No dysplastic or neoplastic changes of the ECL cells in the gastric mucosa have been detected and no patient has developed the carcinoid tumors observed in rats.

Postmarketing Adverse Events

Voluntarily reported adverse events associated with postmarketing experience with the PPIs have been disclosed in the package inserts for all the PPIs.^{9,10,21-24} Postmarketing adverse events have generally been consistent with short-term use of the PPIs and no clear differences between agents have been noted. Blood dyscrasias and serious allergic reactions have been reported. In many cases, a relationship with the PPI could not be established.

Drug Interactions

Drug-Drug Interactions

The two main mechanisms of drug-drug interactions relevant to PPIs are (1) inhibition or induction of CYP450 isoenzymes, and (2) alteration of drug absorption. These interactions are summarized in Table 8.

Omeprazole seems to have the greatest potential to cause CYP450-mediated drug interactions, while lansoprazole, pantoprazole and rabeprazole are less likely to result in such interactions.⁸⁴⁻⁸⁶ Omeprazole inhibits CYPs 2C9 and 2C19. In extensive metabolizers, the inhibition of these isoenzymes by omeprazole has resulted in significant decreases in the clearances of phenytoin, diazepam, and possibly carbamazepine and S-warfarin.⁸⁷ Esomeprazole may reduce the clearance of diazepam by 45% (similar to omeprazole), cause small reductions in phenytoin and R-warfarin metabolism, and cause a small alteration in a minor CYP2C19 metabolic pathway of cisapride.⁸⁸ Rabeprazole is about half as potent as omeprazole in inhibiting CYP2C19 and does not interact with diazepam. CYPs 1A1, 1A2, and 3A4 are induced by omeprazole and lansoprazole but these interactions do not appear to be of clinical relevance, with the exception of a possible reduction in efficacy of oral contraceptives by lansoprazole.^{86,87}

PPIs may decrease or increase the bioavailability of other drugs whose absorption is dependent on gastric pH (see Table 8). The profound inhibition of gastric acid secretion by PPIs results in decreased plasma concentrations of ampicillin, iron salts, and ketoconazole. The same mechanism was the proposed explanation for decreased plasma concentrations of indinavir when given concomitantly with omeprazole.⁸⁹ PPIs are also expected to reduce the absorption of atazanavir⁹⁰ and delavirdine.⁹¹ Increases in digoxin bioavailability have occurred with omeprazole (10% increase in area under the curve)⁹² and rabeprazole (19% increase).^{23,93}

There are few clinically relevant drug interactions with the PPIs.⁸⁶ The most important interaction appears to be the 25% to 50% reduction in clearance of diazepam by omeprazole or esomeprazole via CYP2C19 inhibition in extensive metabolizers,^{86,88} although a similar degree of change in diazepam clearance due to cimetidine was found to be of little clinical consequence.⁹⁴ Other CYP450-metabolized benzodiazepines also have potential to be affected (see Table 8). Possibly clinically relevant interactions due to altered drug absorption are decreases in concentrations of azole antifungal agents (itraconazole, ketoconazole) and antiretroviral agents (atazanavir, delavirdine, indinavir) and increases in digoxin concentrations.

Interactions between warfarin or phenytoin and the PPIs, including omeprazole, do not seem to be clinically relevant when studied in controlled trials.⁸⁶ However, according to FDA adverse event and drug interaction data since drug launch, the most common type of reported interaction with omeprazole, lansoprazole, or pantoprazole involved vitamin K antagonists (e.g., warfarin).⁹⁵ Although pantoprazole is considered to be free of clinically relevant drug interactions, interactions with vitamin K antagonists were reported at similar rates for all three PPIs, albeit rarely. Reports of interactions between these three PPIs and benzodiazepines or phenytoin were even rarer. The FDA postmarketing adverse event data suggest that there is a class effect for interactions between vitamin K antagonists and PPIs, and these interactions may be clinically relevant in certain individuals.

Differences in CYP2C19 genotype have been reported to influence *H. pylori* infection cure rates in dual-drug⁹⁶ and triple-drug^{97,98} regimens with omeprazole and lansoprazole, although other studies have found no effect.⁹⁹⁻¹⁰¹ Clarithromycin has also been shown to increase omeprazole concentrations irrespective of CYP2C19 genotype status,¹⁰² and this interaction could theoretically improve *H. pylori* infection cure rates. Cure rates with rabeprazole, which should be less affected by CYP2C19 genotype, have been conflicting. It has been found to be similar^{98,101} or inferior¹⁰³ to lansoprazole, and similar to omeprazole^{100,103} in triple-drug regimens in extensive metabolizers. Resistance to clarithromycin seems to have a bigger impact on cure rates than CYP2C19 genotype.^{98,99,101}

In summary, few clinically relevant drug-drug interactions are expected with the PPIs. The main clinically relevant difference between PPIs in terms of drug interactions seems to be the potential for omeprazole- or esomeprazole-induced increases in the effects of diazepam and possibly other CYP450-metabolized benzodiazepines. Reduction of the benzodiazepine dose, use of a benzodiazepine that is metabolized by glucuronidation (lorazepam, oxazepam, or temazepam), or the use of another PPI may be a consideration in individuals who develop an adverse interaction from the drug combination.

Table 8 Selected drug interactions involving the proton pump inhibitors

Object drugs that may interact with the proton pump inhibitors						
Mechanism	Effect of object drug	Esomeprazole	Lansoprazole	Omeprazole	Pantoprazole	Rabeprazole
CYP450 inhibition	↑	Benzodiazepines	Warfarin [†]	Benzodiazepines	Warfarin [†]	Clarithromycin ^{**}
		Alprazolam		Alprazolam		Cyclosporin [†]
		Chlordiazepoxide		Chlordiazepoxide		Warfarin [†]
		Clonazepam		Clonazepam		
		Diazepam [†]		Diazepam [†]		
		Flurazepam		Flurazepam		
		Midazolam		Midazolam		
		Triazolam		Triazolam		
		Cisapride		Carbamazepine [†]		
		Phenytoin		Clarithromycin ^{**}		
		Warfarin [†]		Cyclosporin [†]		
				Disulfiram		
				Phenytoin [†]		
		Warfarin [†]				
CYP450 induction	↓	—	OCPs (?) [†] Theophylline	Caffeine	—	—
Decrease GI absorption	↓	Ampicillin	Ampicillin	Ampicillin	Ampicillin	Ampicillin
		Atazanavir [†]	Atazanavir [†]	Atazanavir [†]	Atazanavir [†]	Atazanavir [†]
		Delavirdine [†]	Delavirdine [†]	Delavirdine [†]	Delavirdine [†]	Delavirdine [†]
		Indinavir [†]	Indinavir [†]	Indinavir [†]	Indinavir [†]	Indinavir [†]
		Iron salts	Iron salts	Iron salts	Iron salts	Iron salts
		Itraconazole [†]	Itraconazole [†]	Itraconazole [†]	Itraconazole [†]	Itraconazole [†]
		Ketoconazole [†]	Ketoconazole [†]	Ketoconazole [†]	Ketoconazole [†]	Ketoconazole [†]
Increase GI absorption	↑	Digoxin [†]	Digoxin [†]	Digoxin [†]	—	Digoxin [†]

Sources: 9,10,21-24,84-93,95,102,104-106

The list of drugs in this table is not intended to be all-inclusive. Consult appropriate references for a comprehensive list of drugs that may interact with proton pump inhibitors.

OCP = Oral contraceptive pills

[†] Potential clinically relevant interaction. Increased INR and prothrombin time in patients taking warfarin / vitamin K antagonists and omeprazole, lansoprazole, or pantoprazole have been the most frequently reported drug interaction involving PPIs reported to the FDA, although the frequency was rare.⁹⁵ All PPI package inserts report a potential interaction with warfarin.^{9,10,21-24}

↔ Two-way interaction; clarithromycin may increase plasma omeprazole and esomeprazole concentrations. Omeprazole may increase plasma clarithromycin and 14-hydroxyclearithromycin concentrations. Esomeprazole may increase plasma 14-hydroxyclearithromycin concentrations.

? Unclear effect

Drug-Lab Interactions

Pantoprazole has been associated with false-positive results for tetrahydrocannabinol (THC) on urine screening tests.²¹

Clinical Efficacy

Comparative PPI doses were based on the results of 40 DBRCTs or systematic reviews that compared the PPIs primarily with omeprazole (see Table 9). The relative efficacies were based on subjective (symptom relief) or objective (e.g., endoscopic or pH-metric) measures of response to treatment in patients with duodenal ulcers, *Helicobacter pylori* infection, gastric ulcers, gastroesophageal reflux disease, erosive esophagitis, or dyspepsia.

Table 9 Comparative doses of PPIs

Relative efficacy of PPIs (Doses in mg)		
OME 10 = LAN 15	OME 20 ≤ ESO 20 or 40 ≥ LAN 15 ≤ LAN 30 = PAN 40 ≤ RAB 20	OME 40 or 20 b.i.d. = ESO 20 b.i.d. = LAN 30 > LAN 30 b.i.d. [†] > PAN 40 b.i.d. [†] = RAB 20
LAN 15 < ESO 20	LAN 30 = PAN 40 < ESO 40	LAN 30 b.i.d. = PAN 40 b.i.d.

Sources: 12,17,18,24,29,31-33,56-81,107,108

The comparative doses of proton pump inhibitors (PPIs) were based on relative efficacies reported in double-blind, randomized controlled trials or systematic reviews in patients with gastrointestinal acid-related disorders. Most of the evaluated trials compared lansoprazole or other proton pump inhibitors (PPIs) with omeprazole. Relative efficacy was based on subjective or objective measures of response to treatment in patients with duodenal ulcers, *Helicobacter pylori* infection, gastric ulcers, gastroesophageal reflux disease, erosive esophagitis, or dyspepsia. No trials comparing PPIs in pathologic hypersecretory conditions were found by the literature search.

ESO = Esomeprazole; LAN = Lansoprazole; OME = Omeprazole; PAN = Pantoprazole; RAB = Rabeprazole

= Comparable to; ≤ Inferior or comparable to; ≥ Superior or comparable to

† Unexpected result; see text

In general, standard doses of PPIs (esomeprazole 20 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg) seem to be therapeutically comparable. Likewise, half-doses of PPIs are comparable to each other and inferior to standard doses. Although there have been some differences noted in a few clinical trials for efficacy among different PPIs, a systematic review of this drug class concluded that "In general, there is very little evidence that there are any important differences in the effectiveness or safety of the five PPIs in the general population, or in relevant subgroups."¹⁰⁹

Double doses of a PPI are generally comparable to or better than standard doses and comparable to double doses of other PPIs. The results of a small DBRCT (N = 30) were unexpected in this regard. The study compared twice daily doses of lansoprazole 30 mg, omeprazole 20 mg, and pantoprazole 40 mg as maintenance therapy in patients with severe reflux esophagitis complicated by stricture.⁷⁶ After 4 weeks of treatment, omeprazole (9 of 10, 90%) was statistically significantly superior to either lansoprazole (2 of 10, 20%) or pantoprazole (3 of 10, 30%) in maintaining remission, defined as absence of esophagitis and stricture on endoscopy and absence of symptoms (p < 0.01 for each analysis). No statistically significant difference was noted between lansoprazole and pantoprazole. The authors attributed the treatment differences to intra- and interindividual variability in lansoprazole absorption and to pH-dependent differences in reactivity between omeprazole and pantoprazole in inhibiting H⁺/K⁺-ATPase. Further clinical trials in large patient populations are needed to evaluate relative antisecretory efficacies of PPIs given twice daily.

Therapeutic Interchangeability

Three unpublished studies demonstrated that generic omeprazole is bioequivalent to proprietary omeprazole in healthy volunteers in the fasting state, after food intake, and when the contents of the capsules are sprinkled on applesauce (L. Hinman, Regulatory Affairs, Schwarz Pharma, verbal communication, October 2003). Generic omeprazole is AB-rated by the FDA and is considered to be therapeutically equivalent to proprietary omeprazole.

Six published studies evaluated therapeutic interchange of PPIs: four retrospective analyses from the VA (including a case-control study),¹¹⁰⁻¹¹³ one prospective survey from a managed care organization,¹¹⁴ and one crossover DBRCT from the U.K.⁸² The U.K. study involved switching between omeprazole and rabeprazole, and the remaining five studies involved conversion from omeprazole to lansoprazole.

In two VA studies that reported conversion rates (Table 10), successful conversion was possible in 72% and 95% of patients switched from omeprazole to lansoprazole.^{110,113} Of patients who could not be adequately maintained on lansoprazole in three VA studies, 54% to 72% had unsuccessful conversion because of lack of efficacy and 28% to 45%, because of adverse effects.^{110,111,113} The most common adverse effects were diarrhea and abdominal or chest pain.^{111,113}

One study reported that 94% of patients who were unsuccessfully converted to lansoprazole improved after switching back to omeprazole, and only 8% would consider trying lansoprazole again.¹¹³

Table 10 Published Therapeutic Interchange Studies in the VA: Converting from Omeprazole to Lansoprazole

Reference	Median Dose (Range), mg/d	Successful Conversion	Unsuccessful Conversion	Reason for Unsuccessful Conversions	
				Lack of Efficacy	Adverse Effects
Amidon (2000) ¹¹⁰	OME 20 (20 to 60)	72% (56/78)	28% (22/78)	54.5% (12/22)	45.4% (10/22)
	LAN 30 (15 to 90)				
Gerson (2000) ¹¹³	OME 20 (20 p.r.n. to 80) [†]	95% (3508/3703)	5% (195/3703)	69% (118/172)	30.2% (52/172)
	LAN 30 (15 to ≥ 120) [†]				
Raisch (2001) ¹¹¹	—	—	—	72.5% (37/51)	27.5% (14/51)

[†] Doses used by 172 lansoprazole-intolerant patients

Subsets of patients may experience uncontrolled symptoms, more adverse effects, or a negative impact on health outcomes when switched from one PPI to another.^{82,110-113} This observation is expected after drug conversion, since individual variability in responses to drugs is seen even within the same therapeutic class. Interestingly, perhaps because of a “placebo effect” following conversion, 39 (33.9%) of 115 patients previously considered stable on omeprazole who were then ‘switched’ to blinded omeprazole reported adverse effects, and 7 (6.1%) discontinued medication because of them.⁸²

Population risk factors for unsuccessful conversion or nonresponse to PPI therapy have been identified in two studies. One study found that patients who worsened after being converted from omeprazole to lansoprazole were significantly younger than patients with stable outcomes (mean age, 49.7 years vs. 57.3 years).¹¹⁴ A large nested case-control study (N = 558) found that age over 60 years, heavy smoking, and previous use of PPIs were significantly more common in non-responders to lansoprazole compared with responders.¹¹⁵ Unfortunately, the individuals who will experience unsatisfactory responses cannot be predicted.

Several studies have shown that some individuals who switch PPIs may have a preference for one agent over another.^{82,110,112} However, factors other than PPI effectiveness may influence patient satisfaction with switching agents, such as the method of administering the therapeutic interchange program.¹¹⁴

Overall, the results of these studies support the well-accepted premise that PPIs may be considered therapeutic alternates, and that the majority of patients can be switched from one PPI to another at therapeutically comparable doses (see Table 4 and Table 9) without reduction in effectiveness or tolerability. However, some individuals may be able to distinguish between drugs within the same class and express a preference for one drug over another.

In certain patients, such as those who are on sodium-restricted diets or have acid-base disorders, immediate-release omeprazole / sodium bicarbonate may not be substitutable for delayed-release omeprazole because of the potential risks associated with sodium bicarbonate.

Conclusion

For oral administration, nonproprietary omeprazole can be used for generic substitution of proprietary omeprazole (Prilosec). Proprietary omeprazole should be used for compounding Simplified Omeprazole Suspension and mixing in orange juice until the stability and equivalent intragastric pH effects of generic omeprazole in such formulations can be verified.

The PPIs may be considered for therapeutic interchange because of their comparable pharmacologic properties and clinical efficacy and safety profiles. In general, PPIs are therapeutically comparable at the same dosage levels (half-, standard-, or double-dose). Consistent results of clinical trials in patients with duodenal ulcers, gastric ulcers, GERD, hypersecretory conditions, and other acid-related disorders strongly suggest that there is a class effect of PPIs for these disorders, although differences in dosage formulations and drug interactions may occasionally influence choice of PPI in individual cases.

References

1. Phillips JO, Metzler MH, Johnson M. The stability of simplified omeprazole suspension (SOS) (abstract). *Critical Care Medicine* 1998;28:A221.
2. Phillips JO, Metzler MH, Palmieri MT, Huckfeldt RE, Dahl NG. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. *Crit Care Med* 1996;24:1793-800.
3. Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. *Am J Health Syst Pharm* 1999;56:S18-21.
4. Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. *J Trauma* 1998;44:527-33.
5. Phillips JO, Olsen KM, Rebuck JA, Rangnekar NJ, Miedema BW, Metzler MH. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. *Am J Gastroenterol* 2001;96:367-72.
6. Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension--a liquid formulation of lansoprazole--effectively suppresses intragastric acidity when administered through a gastrostomy. *Am J Gastroenterol* 1999;94:1813-7.
7. Phillips JO, Metzler MH. The stability of simplified lansoprazole suspension (SLS) (abstract). *Gastroenterology* 1999;116:A89.
8. Taubel JJ, Sharma VK, Chiu YL, Lukasik NL, Pilmer BL, Pan WJ. A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH. *Aliment Pharmacol Ther* 2001;15:1807-17.
9. AstraZeneca. Prilosec [package insert online]. July 2002. Available at: www.astrazeneca-us.com/pi/Prilosec.pdf. In: AstraZeneca LP; 2002.
10. Kremers Urban. Omeprazole [package insert online]. June 2003. Available at: <http://www.ppiq.com/pdf/OmeprazolePI.pdf>. In: Mequon, WI; 2003.
11. Bianchi Porro G, Lazzaroni M, Imbesi V, Montrone F, Santagada T. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. *Dig Liver Dis* 2000;32:201-8.
12. Witzel L, Gutz H, Huttemann W, Schepp W. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. *Aliment Pharmacol Ther* 1995;9:19-24.
13. Meneghelli UG, Zaterka S, de Paula Castro L, Malafaia O, Lyra LG. Pantoprazole versus ranitidine in the treatment of duodenal ulcer: a multicenter study in Brazil. *Am J Gastroenterol* 2000;95:62-6.
14. Chen TS, Chang FY, Ng WW, Lee FY, Hwang SJ, Lee SD. The efficacy of the third pump inhibitor--pantoprazole--in the short-term treatment of Chinese patients with duodenal ulcer. *Hepatogastroenterology* 1999;46:2372-8.
15. Cremer M, Lambert R, Lamers CB, Delle Fave G, Maier C. A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group. *Dig Dis Sci* 1995;40:1360-4.
16. Schepp W, Classen M. Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. *Scand J Gastroenterol* 1995;30:511-4.
17. Rehner M, Rohner HG, Schepp W. Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study. *Aliment Pharmacol Ther* 1995;9:411-6.
18. Beker JA, Bianchi Porro G, Bigard MA et al. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. *Eur J Gastroenterol Hepatol* 1995;7:407-10.
19. Judmaier G, Koelz HR. Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group. *Aliment Pharmacol Ther* 1994;8:81-6.
20. Anonymous. Drug Facts and Comparisons online. eFacts, Wolters Kluwer Health, Inc. Available at: <http://www.efactsweb.com>.
21. Wyeth Laboratories. Protonix [package insert online]. June 2003. Available at: <http://www.wyeth.com/content/ShowLabeling.asp?id=135>. In: Philadelphia, PA: Wyeth Laboratories; 2003.
22. TAP. Prevacid [package insert online]. August 2003. Available at: http://www.prevacid.com/prescribing_information.asp. In: Lake Forest, IL: TAP Pharmaceuticals Inc.; 2003.
23. Eisai / Janssen. Aciphex [package insert online]. November 2002. Available at: <http://www.aciphex.com/aciphexpi.pdf>. In: New Jersey; 2002.
24. AstraZeneca. Nexium [package insert online]. March 2003. Available at: <http://www.astrazeneca-us.com/pi/Nexium.pdf>. In: Wilmington, DE: AstraZeneca LP; 2003.
25. Anonymous. Off-Label Drug Facts. St. Louis: Wolter Kluwer Co.; 2003.
26. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. *Am J Gastroenterol* 2000;95:3071-80.

27. van Zyl JH, de KGH, van Rensburg CJ et al. Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study. *Eur J Gastroenterol Hepatol* 2000;12:197-202.
28. Koop H, Schepp W, Dammann HG, Schneider A, Luhmann R, Classen M. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study. *J Clin Gastroenterol* 1995;20:192-5.
29. Delchier JC, Cohen G, Humphries TJ. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastroesophageal reflux disease. *Scand J Gastroenterol* 2000;35:1245-50.
30. Farley A, Wruble LD, Humphries TJ. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Rabeprazole Study Group. *Am J Gastroenterol* 2000;95:1894-9.
31. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. *Aliment Pharmacol Ther* 1999;13:49-57.
32. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. *Aliment Pharmacol Ther* 1999;13:179-86.
33. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group. *Aliment Pharmacol Ther* 1998;12:789-95.
34. Cammarota G, Cianci R, Cannizzaro O et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2000;14:1339-43.
35. Humphries TJ, Rindi G, Fiocca R. Pilot studies on the effects of rabeprazole sodium (E3810), amoxicillin, and placebo on the eradication of *H. pylori*. *Am J Gastroenterol* 1996;91:1914.
36. Kihira K, Satoh K, Saifuku K et al. Rabeprazole, amoxicillin and low- or high-dose clarithromycin for cure of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2000;14:1083-7.
37. Lueth S, Teyssen S, Singer M. A four day triple therapy with rabeprazole, amoxicillin and clarithromycin in patients with peptic ulcer disease and *Helicobacter pylori* infection is safe and effective in 90%--a pilot study (abstract). *Am J Gastroenterol* 2000;95:2435.
38. Miwa H, Ohkura R, Murai T et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for *Helicobacter pylori* infection-comparison with omeprazole and lansoprazole. *Aliment Pharmacol Ther* 1999;13:741-6.
39. Miwa H, Yamada T, Sato K et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for *Helicobacter pylori* infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. *Dig Dis Sci* 2000;45:77-82.
40. Nagahara A, Miwa H, Ogawa K et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for *Helicobacter pylori* infection provides an excellent cure rate with five-day therapy. *Helicobacter* 2000;5:88-93.
41. Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2001;15:417-21.
42. Stack WA, Knifton A, Thirlwell D et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of *Helicobacter pylori* in patients with chronic gastritis with or without peptic ulceration. *Am J Gastroenterol* 1998;93:1909-13.
43. Miner P, Fillipone J, Jokubaitis L, et al. Rabeprazole results in global improvement in symptoms of nonerosive gastroesophageal reflux disease. *Am J Gastroenterol* 2000;95:A2435.
44. Miner P, Fillipone J, Jokubaitis L, et al. Rabeprazole relieves heartburn and associated symptoms in nonerosive gastroesophageal reflux disease. *Am J Gastroenterol* 2000;95:A2435.
45. Wyeth Pharmaceuticals. Protonix I.V. [prescribing information online]. June 2003. Available at: <http://www.wyeth.com/content/ShowLabeling.asp?id=136>. In Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2003.
46. Noordzij JP, Khidr A, Evans BA et al. Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. *Laryngoscope* 2001;111:2147-51.
47. Pandak WM, Arezo S, Everett S et al. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. *J Clin Gastroenterol* 2002;35:307-14.
48. Xia HH, Lai KC, Lam SK et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. *Aliment Pharmacol Ther* 2003;17:369-77.
49. Kaviani MJ, Hashemi MR, Kazemifar AR et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. *Aliment Pharmacol Ther* 2003;17:211-6.
50. Javid G, Masoodi I, Zargar SA et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. *Am J Med* 2001;111:280-4.

Formatted: French (France)

Formatted: French (France)

Formatted: French (France)

51. Baldi F, Morselli-Labate AM, Cappiello R, Gherzi S. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. *Am J Gastroenterol* 2002;97:1357-64.
52. Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. *Aliment Pharmacol Ther* 2001;15:347-54.
53. Lind T, Havelund T, Lundell L et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial. *Aliment Pharmacol Ther* 1999;13:907-14.
54. Talley NJ, Venables TL, Green JR et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. *Eur J Gastroenterol Hepatol* 2002;14:857-63.
55. Mohiuddin MA, Pursnani KG, Katzka DA, Gideon RM, Castell JA, Castell DO. Effective gastric acid suppression after oral administration of enteric-coated omeprazole granules. *Dig Dis Sci* 1997;42:715-9.
56. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. *Eur J Gastroenterol Hepatol* 1995;7:661-5.
57. Chang FY, Chiang CY, Tam TN, Ng WW, Lee SD. Comparison of lansoprazole and omeprazole in the short-term management of duodenal ulcers in Taiwan. *J Gastroenterol Hepatol* 1995;10:595-601.
58. Ekstrom P, Carling L, Unge P, Anker-Hansen O, Sjostedt S, Sellstrom H. Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study. *Scand J Gastroenterol* 1995;30:210-5.
59. Dobrilla G, Piazzzi L, Fiocca R. Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial. *Clin Ther* 1999;21:1321-32.
60. Sito E, Konturek PC, Bielanski W et al. One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients. *J Physiol Pharmacol* 1996;47:221-8.
61. Hawkey CJ, Atherton JC, Treichel HC, Thjodleifsson B, Ravic M. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. *Aliment Pharmacol Ther* 2003;17:1065-74.
62. Veldhuyzen Van Zanten S, Lauritsen K, Delchier JC et al. One-week triple therapy with esomeprazole provides effective eradication of helicobacter pylori in duodenal ulcer disease [In Process Citation]. *Aliment Pharmacol Ther* 2000;14:1605-11.
63. Veldhuyzen Van Zanten S, Machado S, Lee J. One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. *Aliment Pharmacol Ther* 2003;17:1381-7.
64. Lind T, Rydberg L, Kyleback A et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. *Alimentary Pharmacology & Therapeutics* 2000;14:861-7.
65. Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencyla JL. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. *Am J Gastroenterol* 2001;96:3089-98.
66. Richter JE, Kahrilas PJ, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. *Am J Gastroenterol* 2001;96:656-65.
67. Kahrilas PJ, Falk GW, Johnson DA et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. *Alimentary Pharmacology & Therapeutics* 2000;14:1249-1258.
68. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. *Can J Gastroenterol* 1997;11 Suppl B:66B-73B.
69. Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. *Aliment Pharmacol Ther* 2001;15:227-31.
70. Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. *Aliment Pharmacol Ther* 1996;10:757-63.
71. Hatlebakk JG, Berstad A, Carling L et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. *Scand J Gastroenterol* 1993;28:224-8.
72. Mossner J, Holscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. *Aliment Pharmacol Ther* 1995;9:321-6.
73. Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group. *Eur J Gastroenterol Hepatol* 1996;8:1101-6.
74. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2002;16:479-85.

75. Thjodleifsson B, Bekker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. *Dig Dis Sci* 2000;45:845-53.
76. Jaspersen D, Diehl KL, Schoepfner H, Geyer P, Martens E. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. *Aliment Pharmacol Ther* 1998;12:49-52.
77. Thjodleifsson B, Rindi G, Fiocca R et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. *Aliment Pharmacol Ther* 2003;17:343-51.
78. Jones R, Crouch SL. Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. *Aliment Pharmacol Ther* 1999;13:413-9.
79. Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. *Am J Gastroenterol* 2002;97:575-83.
80. Lauritsen K, Deviere J, Bigard MA et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. *Aliment Pharmacol Ther* 2003;17:333-41.
81. Dupas JL, Houcke P, Samoyeau R. Pantoprazole versus lansoprazole in French patients with reflux esophagitis. *Gastroenterol Clin Biol* 2001;25:245-50.
82. Johnson M, Guilford S, Libretto SE. Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole. *Curr Med Res Opin* 2002;18:303-10.
83. Genta RM, Rindi G, Fiocca R, Magner DJ, D'Amico D, Levine DS. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. *Am J Gastroenterol* 2003;98:1257-65.
84. Lew EA. Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy. *Aliment Pharmacol Ther* 1999;13 Suppl 5:11-6.
85. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. *Aliment Pharmacol Ther* 1999;13 Suppl 3:18-26.
86. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. *Eur J Gastroenterol Hepatol* 2001;13:611-6.
87. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. *Aliment Pharmacol Ther* 2000;14:963-78.
88. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. *Clin Pharmacokinet* 2001;40:523-37.
89. Burger DM, Hugen PW, Kroon FP et al. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. *AIDS* 1998;12:2080-2.
90. eFacts. Drug Interaction Facts online. Wolters Kluwer Health, Inc. Available at: <http://www.efactsweb.com/Index.asp>.
91. Agouron Pharmaceuticals. Rescriptor (delavirdine) [package insert online]. 7 Dec 2001. Pfizer. Available at: http://www.pfizer.com/download/uspi_rescriptor.pdf. Accessed 14 Oct 2003.
92. Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. *Br J Clin Pharmacol* 1991;32:569-72.
93. Humphries TJ, Spera AC, Laurent AL, Spanyers SA. Coadministration of rabeprazole sodium (E3810) and digoxin results in a predictable interaction (abstract). *Am J Gastroenterol* 1996;91:1914.
94. Greenblatt DJ, Abernethy DR, Morse DS, Harmatz JS, Shader RI. Clinical importance of the interaction of diazepam and cimetidine. *N Engl J Med* 1984;310:1639-43.
95. Labenz J, Petersen KU, Rosch W, Koelz HR. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. *Aliment Pharmacol Ther* 2003;17:1015-9.
96. Furuta T, Ohashi K, Kamata T et al. Effect of genetic differences in omeprazole metabolism on cure rates for *Helicobacter pylori* infection and peptic ulcer. *Ann Intern Med* 1998;129:1027-30.
97. Furuta T, Shirai N, Takashima M et al. Effect of genotypic differences in CYP2C19 on cure rates for *Helicobacter pylori* infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. *Clin Pharmacol Ther* 2001;69:158-68.
98. Kawabata H, Habu Y, Tomioka H et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of *Helicobacter pylori* infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. *Aliment Pharmacol Ther* 2003;17:259-64.
99. Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N. Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of *H. pylori* infection: a multiple logistic regression analysis. *Dig Dis Sci* 2001;46:2445-50.

100. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxicillin and clarithromycin in Japan. *Dig Liver Dis* 2001;33:671-5.
101. Miki I, Aoyama N, Sakai T et al. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. *Eur J Gastroenterol Hepatol* 2003;15:27-33.
102. Furuta T, Ohashi K, Kobayashi K et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. *Clin Pharmacol Ther* 1999;66:265-74.
103. Inaba T, Mizuno M, Kawai K et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. *J Gastroenterol Hepatol* 2002;17:748-53.
104. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. *Clin Pharmacokinet* 1996;31:9-28.
105. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. *Aliment Pharmacol Ther* 1999;13 Suppl 3:27-36.
106. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. *Pharmacotherapy* 1998;18:84-112.
107. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. *Clin Ther* 2001;23:998-1017.
108. Janczewska I, Sagar M, Sjostedt S, Hammarlund B, Iwarzon M, Seensalu R. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. *Scand J Gastroenterol* 1998;33:1239-43.
109. McDonagh MS, Carson S. Drug Class Review on Proton Pump Inhibitors. 2006. Accessed: 27 July 2006. Available at: <http://www.ohsu.edu/drugeffectiveness/reports/final.cfm>.
110. Amidon PB, Jankovich R, Stoukides CA, Kaul AF. Proton pump inhibitor therapy: preliminary results of a therapeutic interchange program. *Am J Manag Care* 2000;6:593-601.
111. Raisch DW, Klaurens LM, Hayden C, Malagon I, Pulliam G, Fass R. Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms. *Dig Dis Sci* 2001;46:1533-9.
112. Condra LJ, Morreale AP, Stolley SN, Marcus D. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. *Am J Manag Care* 1999;5:631-8.
113. Gerson LB, Hatton BN, Ryono R et al. Clinical and fiscal impact of lansoprazole intolerance in veterans with gastroesophageal reflux disease. *Aliment Pharmacol Ther* 2000;14:397-406.
114. Nelson WW, Vermeulen LC, Geurkink EA, Ehlert DA, Reichelderfer M. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. *Arch Intern Med* 2000;160:2491-6.
115. Claessens AA, Heerdink ER, Lamers CB, van Eijk JT, Leufkens HG. Factors associated with non-response in proton pump inhibitor users: a study of lansoprazole therapy. *Pharm World Sci* 2001;23:107-10.

Prepared: June 2006. Contact person: F. Goodman, PharmD, BCPS
